Part 2: Future Treatment Options and Roles for Pharmacists in Individualizing Insulin Therapy
In Part 2 of this two-part “Engaging the Experts” interview, William Zellmer talks with Curtis L. Triplitt, Susan Cornell, and Joshua J. Neumiller regarding future treatment options for type 2 diabetes and the roles for pharmacists in individualizing insulin therapy. This installment is produced by A S H P Advantage and supported by Novo Nordisk Inc.
Faculty:
Curtis Triplitt, PharmD, CDE
Associate Director, Diabetes Research Center, Texas Diabetes Institute
Associate Professor, Department of Medicine, Division of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Susan Cornell, PharmD, CDE, FAPhA, FAADE
Associate Director of Experiential Education
Associate Professor, Department of Pharmacy Practice
Midwestern University Chicago College of Pharmacy
Downers Grove, Illinois
Joshua Neumiller, PharmD, CDE, FASCP
Vice Chair and Associate Professor, Department of Pharmacotherapy
Washington State University College of Pharmacy
Spokane, Washington
C.E. Credits: This activity is not eligible for continuing education credits.